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The recovery status from delayed 
graft function can predict long-term 
outcome after deceased donor 
kidney transplantation
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The effect of delayed graft function (DGF) recovery on long-term graft outcome is unclear. The aim of 
this study was to examine the association of DGF recovery status with long-term outcome. We analyzed 
385 recipients who underwent single kidney transplantation from brain-dead donors between 2004 
and 2015. Patients were grouped according to renal function at 1 month post-transplantation: control 
(without DGF); recovered DGF (glomerular filtration rate [GFR] ≥ 30 mL/min/1.73 m2); and incompletely 
recovered DGF group (GFR < 30 mL/min/1.73 m2). DGF occurred in 104 of 385 (27%) recipients. Of the 
DGF patients, 70 recovered from DGF and 34 incompletely recovered from DGF. Death-censored graft 
survival rates for control, recovered DGF, and incompletely recovered DGF groups were 95.3%, 94.7%, 
and 80.7%, respectively, at 5 years post-transplantation (P = 0.003). Incompletely recovered DGF was 
an independent risk factor for death-censored graft loss (HR = 3.410, 95%CI, 1.114-10.437). DGF was 
associated with increased risk for patient death regardless of DGF recovery status. Mean GFRs at 5 years 
were 65.5 ± 20.8, 62.2 ± 27.0, and 45.8 ± 15.4 mL/min/1.73 m2 for control, recovered, and incompletely 
recovered DGF groups, respectively (P < 0.001). Control group and recovered DGF patients had similar 
renal outcomes. However, DGF was associated with increased risk for patient death regardless of DGF 
recovery status.
Delayed graft function (DGF) is a common complication after deceased donor kidney transplantation. The asso-
ciation between organ quality and DGF is well established1. Notwithstanding that association, there has been 
increasing use of marginal kidneys due to a critical shortage of organs2,3. As a consequence, the incidence of DGF 
remains high.
In spite of the high incidence, the influence of DGF on long-term outcome is unclear4. The lack of uniform 
DGF definition complicates comparison of research data5. In addition, DGF is caused by complex factors with 
varying severities. The severity of injury can affect the degree of recovery6. Moreover, there are recent reports 
indicating that incomplete recovery from acute kidney injury (AKI) is an important contributor to the progres-
sion of chronic kidney disease7,8. In the transplantation setting, however, prior studies have focused on the devel-
opment of DGF per se, not only recovery of DGF. For this study, we hypothesised that recovery status might elicit 
different long-term outcomes.
Some studies have stratified DGF recovery according to dialysis duration9–13. However, the decision to dis-
continue dialysis after DGF is subjective, and currently, there is a lack of consensus for defining DGF recovery. 
In addition, there are no clearly defined predictive biomarkers for DGF prognosis despite rigorous research14. 
From a practical point of view, renal function after recovery from DGF is probably the best marker for long-term 
prognosis15–17, and glomerular filtration rate (GFR) is accepted as an accurate parameter when assessing renal 
function18. Therefore, we compared transplant outcomes in recipients who exhibited DGF according to DGF 
recovery status based on GFR.
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Material and Methods
Patients. A retrospective review of a prospectively collected database of kidney transplants at Severance 
Hospital revealed 423 adult patients who underwent deceased donor kidney transplantation between 2004 and 
2015. Exclusion criteria were simultaneous non-kidney transplantation, en bloc kidney transplantation, and pri-
mary non-function. Patients with missing data on donor cause of death, final serum creatinine, donor hyperten-
sion, or donor diabetes were excluded. All donors were brain dead.
Patients with DGF were grouped into the recovered DGF (GFR ≥ 30 mL/min/1.73 m2) or incompletely recov-
ered DGF (GFR < 30 mL/min/1.73 m2) groups according to renal function at 1 month post-transplantation. 
Patients without DGF were assigned to the control group (Fig. 1).
Definitions. DGF was defined as the need for at least one dialysis session within the first week after kidney 
transplantation5. Expanded criteria donors (ECD) included all donors ≥60 years old and donors ≥50 years old 
with at least two of the following conditions: history of hypertension; cerebrovascular cause of brain death; or 
final creatinine >1.5 mg/dL.
Immunosuppression. All patients received induction therapy with basiliximab or anti-thymocyte globulin 
(ATG). We selected the induction therapy based on the donor/recipient characteristics and postoperative pro-
gress of the patient. Maintenance immunosuppression consisted of calcinurin inhibitors (tacrolimus or cyclo-
sporine), prednisolone, and mycophenolate mofetil (MMF) or mycophenolate sodium (MPS). Initial tacrolimus 
was administered orally at 0.1 mg/kg twice daily. Subsequent doses were adjusted to maintain a target trough con-
centration between 3 and 8 ng/mL. Initial oral dose of cyclosporine was 5 mg/kg twice daily, and it was adjusted 
to achieve a trough level of 100–200 ng/mL. The initial dose of methylprednisolone (500–1000 mg) was gradually 
reduced to oral prednisolone (5–10 mg/day) during the first 3 weeks after transplantation. Patients received either 
MMF of 1000–2000 mg/day or MPS of 720–1440 mg/day.
Outcome assessment. Graft loss was defined as return to long-term dialysis, re-transplant, or death with a 
functioning graft. Graft loss was defined as return to long-term dialysis, re-transplant, or death with a function-
ing graft. Graft survival was calculated from the date of transplantation to the date of graft loss or June 30, 2016 
(end of follow-up period). In cases of death with a functioning graft, graft survival was censored at the time of 
death. Patient survival was defined as the length of time from transplantation to the date of death or the date of 
last follow-up.
All acute rejection (AR) episodes were biopsy proven and classified according to Banff criteria. ARs were clas-
sified as acute cellular rejection (ACR) or antibody-mediated rejection (AMR). Biopsies that revealed borderline 
changes were excluded. For patients with more than one episode of AR, only the first rejection was included in 
our statistical analysis. Protocol biopsies were not performed during the study period.
Renal function was assessed by using GFR estimated by the modification of diet in renal disease formula 
(MDRD).
Statistical analysis. Demographic information was summarised using frequency (percentage), or 
mean ± standard deviation value, depending on data type. Chi-square tests with Fisher’s exact tests were used 
to compare categorical variables and one-way Analysis of Variance was used to compare continuous variables. 
When the data revealed a statistically significant difference, post hoc comparisons were performed by applying 
Figure 1. Study flow diagram.
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Bonferroni’s correction for multiple comparisons. Survival and freedom from events were estimated by using 
the Kaplan-Meier method and were statistically compared by using log-rank tests. Univariate and multivari-






DGF (n = 34) P-value
Recipient age at KT 46.89 ± 10.70 46.86 ± 10.58 48.77 ± 10.33 0.617
Male recipient (%) 165 (58.7%) 38 (54.3%) 19 (55.9%) 0.847
Diabetes as the cause of ESRD 31 (11.0%) 10 (14.3%) 5 (14.7%) 0.659
Number of HLA mismatches 2.75 ± 1.55 3.11 ± 1.26 3.01 ± 1.52 0.121
Recipient BMI (kg/m2) 22.29 ± 3.41 22.76 ± 3.33 22.19 ± 2.58 0.545
Pretransplant dialysis duration (m) 81.31 ± 47.45 93.79 ± 45.63 86.21 ± 47.12 0.136
Re-transplantation 43 (15.3%) 12 (17.1%) 7 (20.6%) 0.706
Donor age at KT 44.02 ± 13.85 45.66 ± 11.11 49.68 ± 11.68 0.053
Male donor (%) 181 (64.4%) 44 (62.9%) 21 (61.8%) 0.936
Donor BMI (kg/m2) 23.08 ± 3.68 22.86 ± 3.37 24.37 ± 4.47 0.122
Mean final serum Cr (mg/dL) 1.21 ± 0.75 1.97 ± 1.41 1.96 ± 1.24  < 0.001*
Donor history of HTN (%) 61 (21.7%) 17 (24.3%) 11 (32.4%) 0.368
Donor history of DM (%) 19 (6.8%) 2 (2.9%) 4 (11.8%) 0.736
Expanded criteria donor (%) 70 (24.9%) 24 (34.3%) 14 (41.2%) 0.060
Cold ischemic time 0.128
    <4 hours 90 (32.3%) 22 (31.4%) 9 (25.7%)
    4–8 hours 160 (57.3%) 36 (51.4%) 20 (57.1%)
    8–12 hours 20 (7.2%) 10 (14.3%) 3 (8.6%)
    >12 hours 9 (3.2%) 2 (2.9%) 3 (8.6%)
Induction therapy (%) <0.001*
    ATG 22 (11.7%) 31 (44.3%) 19 (55.9%)
    Basiliximab 259 (92.2%) 39 (55.7%) 15 (44.1%)
CNI at discharge (%) 0.419
    Tacrolimus 223 (79.4%) 51 (72.9%) 28 (82.4%)
   Cyclosporine 58 (20.6%) 19 (27.1%) 6 (17.6%)
PRA (%) 0.128
    0% 153 (54.4%) 37 (52.9%) 12 (35.3%)
    1 – 20% 44 (15.7%) 6 (8.6%) 6 (17.6%)
    21 – 80% 55 (19.6%) 18 (25.7%) 13 (38.2%)
    >80% 29 (10.3%) 9 (12.9%) 3 (8.8%)
Table 1. Baseline characteristics by DGF recovery status. DGF = delayed graft function, KT = kidney 
transplantation, DM = diabetes mellitus, ESRD = end stage renal disease, HLA = human leukocyte 
antigen, BMI = body mass index, Cr = creatinine, HTN = hypertension, ATG = anti-thymocyte globulin, 
CNI = calcinurin inhibitor, PRA = panel reactive antibodies. *Post hoc Bonferroni: P < 0.05 in all comparisons 
except recovered DGF vs. incompletely recovered DGF.
Univariate Multivariate
HR (95% CI) P-value HR (95% CI) P-value
DGF status
     Recovered 1.549 (0.550, 4.360) 0.407 1.690 (0.574, 4.972) 0.341
     Incompletely recovered 4.745 (1.785, 12.619) 0.002 3.410 (1.114, 10.437) 0.032
Acute rejection 4.869 (2.046, 11.583) <0.001 2.876 (1.064, 7.776) 0.037
HLA mismatches ≥5 1.754 (0.595, 5.173) 0.308
Recipient age 1.002 (0.962, 1.043) 0.918
Old donor (≥60 years old) 3.655 (1.442, 9.264) 0.006 1.665 (0.568, 4.882) 0.353
Cold ischemic time 1.061 (0.930, 1.209) 0.379
Donor creatinine (>1.5 mg/dL) 0.491 (0.183, 1.316) 0.158 0.432 (0.152, 1.225) 0.115
Diabetes as the cause of ESRD 1.476 (0.437, 4.981) 0.531
Pretransplant dialysis duration (>10 years) 2.200 (0.866, 5.586) 0.097
Table 2. Risk factor analysis for death-censored graft failure. DGF = delayed graft function, ESRD = end stage 
renal disease.
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death-censored graft loss, patient death, and incompletely recovered DGF. We included in the multivariate anal-
ysis factors significantly differing among the groups in the univariate analyses and also the clinically relevant fac-
tors in this respect. Statistical analyses were performed by using SPSS software (version 23.0; SPSS Inc., Chicago, 
IL, USA), and P-values < 0.05 were considered statistically significant.
Ethics statement. The study procedures were in accordance with the Declaration of Helsinki and were 
approved by the Institutional Review Board of Severance Hospital (4-2016-1016). Informed consent was waived 
by the Institutional Review Board because of the study’s retrospective design.
Figure 2. Graft and patient survival according to delayed graft function status. (a) Graft survival. (b) Death-
censored graft survival. (c) Patient survival.
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Results
Baseline characteristics. A total of 385 patients were included in the study, and DGF occurred in 104 
of 385 (27%) recipients. Of the 104 patients with DGF, 70 were in the recovered DGF group and 34 were in the 
incompletely recovered DGF group. Table 1 summarises the baseline characteristics of the patients stratified by 
DGF recovery status. The median duration of follow-up was 47 months post-transplantation.
There were no significant differences between recipient characteristics among the three groups. The mean 
level of donor serum creatinine before donation was significantly higher in the DGF group, regardless of recovery 
status, than in the control group. In the incompletely recovered DGF group, donors were older and ECD were 
more common compared to those in the recovered DGF group, but the differences were not statistically signifi-
cant. There was no significant difference in cold ischemic time (CIT) distribution among the groups. Maintenance 
immunosuppressive regimens were comparable among the groups. Compared to patients without DGF, patients 
with DGF, regardless of recovery status, were more likely to receive ATG induction. However, the rates of ATG 
induction were similar between the recovered and incompletely recovered DGF groups.
Patient and graft survival. Graft and patient survival results are presented in Fig. 2. Five-year all-cause 
graft losses were 8.2%, 18.3%, and 32.9% for control, recovered DGF, and incompletely recovered DGF groups, 
respectively (P < 0.001). Twenty-four patients died with functioning grafts, accounting for 50% of all graft losses. 
The predominant cause of death in all groups was infectious diseases (Fig. 3). Death-censored graft survival for 
control, recovered DGF, and incompletely recovered DGF groups were 95.3%, 94.7%, and 80.7%, respectively, at 
5 years post-transplantation (P = 0.003). Death-censored graft survival was comparable between the control and 
recovered DGF groups (P = 0.4). Incompletely recovered DGF and acute rejection were independent risk factors 
for death-censored graft loss (Table 2).
Patient survival did not differ between the recovered and incompletely recovered DGF groups. Five-year 
patient survival rates were 95.6%, 85.0%, and 83.2%, for control, recovered, and incompletely recovered DGF 
groups, respectively (P < 0.001). Multivariate analysis showed that recipient age, prolonged pretransplant dialysis, 
and DGF regardless of recovery status were associated with patient death (Table 3).
Renal function. The mean GFRs were consistently lower in the incompletely recovered DGF group 
than in the control and recovered DGF groups throughout the follow-up period (Fig. 4). Compared to the 
Figure 3. Causes for patient death. CVD: cardiovascular diseases.
Univariate Multivariate
HR (95% CI) P-value HR (95% CI) P-value
DGF status
     Recovered 3.622 (1.471, 8.919) 0.005 3.029 (1.135, 8.082 0.027
     Incompletely recovered 5.482 (1.991, 15.092) 0.001 3.524 (1.189, 10.441) 0.023
Acute rejection 3.014 (1.254, 7.240) 0.014 2.312 (0.896, 5.968) 0.083
HLA mismatches ≥5 1.852 (0.632, 5.428) 0.262
Recipient age 1.070 (1.026, 1.117) 0.002 1.063 (1.013, 1.116) 0.013
Old donor (≥60 years old) 0.839 (0.198, 3.565) 0.812 0.474 (0.108, 2.080) 0.322
Cold ischemic time 1.073 (0.942, 1.223) 0.289
Donor creatinine (>1.5 mg/dL) 1.102 (0.487, 2.495) 0.816 0.681 (0.276, 1.683) 0.405
Diabetes as the cause of ESRD 1.656 (0.567, 4.837) 0.356
Pretransplant dialysis duration (>10 years) 4.133 (1.834, 9.314) 0.001 2.989 (1.303, 6.856) 0.010
Table 3. Risk factor analysis for patient death. DGF = delayed graft function, ESRD = end stage renal disease.
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incompletely recovered DGF group, graft function in the recovered DGF group recovered well and remained sta-
ble. From 6 months on, mean GFRs of the recovered DGF and control groups were similar. Mean GFRs at 5-year 
post-transplantation were 65.5 ± 20.8, 62.2 ± 27.0, and 45.8 ± 15.4 mL/min/1.73 m2 for control, recovered DGF, 
and incompletely recovered DGF groups, respectively (P < 0.001).
Acute rejection. One-year cumulative probabilities of AR in the control, recovered DGF, and incom-
pletely recovered DGF groups were 10.3%, 17.1%, and 23.5%, respectively (log-rank P = 0.02). Among the 49 
patients with AR, approximately two-thirds of ARs (33/49, 67.3%) occurred within 4 months of transplan-
tation. The histologic features of AR are summarised in Table 4. In the incompletely recovered DGF group, 
severe ACRs were more common than those of the control and recovered DGF groups, but the differences were 
not statistically significant. The incidences of AMR were not significantly different among the three groups.
Risk factors associated with incompletely recovered DGF. Multivariate analysis showed that CIT, 
donor final creatinine, and old donor were associated with incompletely recovered DGF (Table 5).
Figure 4. Renal function according to DGF recovery status.
Univariate Multivariate
HR (95% CI) P-value HR (95% CI) P-value
Recipient Age 1.005 (0.984, 1.027) 0.628
Diabetes as the cause of ESRD 1.268 (0.466, 3.456) 0.642
HLA mismatches ≥5 1.075 (0.310, 3.730) 0.910
Retransplantation 1.395 (0.579, 3.363) 0.458
Donor age <40 years old
                  40–60 years old 2.130 (0.843, 5.381) 0.110 2.304 (0.874, 6.071) 0.091
                   >60 years old 3.305 (0.942, 11.589) 0.062 4.761 (1.215, 18.655) 0.025
Cold ischemic time (per hour) 3.767 (1.144, 12.401) 0.029 1.175 (1.051, 1.313) 0.005
Donor final creatinine (mg/dL) 1.442 (1.108, 1.876) 0.006 1.515 (1.138, 2.017) 0.004
Donor HTN 1.674 (0.782, 3.584) 0.185 1.085 (0.472, 2.494) 0.848
Donor diabetes 2.095 (0.675, 6.504) 0.201
Pretransplant dialysis duration (>10 years) 1.463 (0.632, 3.385) 0.374
Table 5. Risk factor analysis for incompletely recovered DGF. DGF = delayed graft function, ESRD = end stage 
renal disease, HTN = hypertension.
No DGF (n = 281) Recovered DGF (n = 70) Incompletely recovered DGF (n = 34) P-value
Overall acute rejection 29 (10.3%) 12 (17.1%) 8 (23.5%) 0.046*
Acute cellular rejection 0.075
    Grade I 14 (5.0%) 3 (4.3%) 2 (5.9%)
    Grade II/III 5 (1.8%) 4 (5.7%) 4 (11.8%)
Acute antibody-mediated rejection 0.273
    Pure antibody-mediated rejection 6 (2.1%) 3 (4.3%) 2 (5.9%)
    Mixed rejection 4 (1.4%) 2 (2.9%) 0
Table 4. Histologic features of acute rejection. *Post hoc Bonferroni: P < 0.05 in comparison between control vs. 
incompletely recovered DGF.
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Discussion
While the negative consequences of DGF on clinical outcome have been described in many reports, the impact of 
DGF recovery status on graft outcome has not been reported4,19. Defining DGF recovery based on recent AKI cri-
teria is challenging because baseline renal function has not been fully elucidated20. Hence, in this study, we apply 
threshold values for GFR based on chronic kidney disease stage (i.e., stage 4 [GFR < 30 mL/min/1.73 m2]: severely 
reduced renal function), which has been verified and widely used21. Our study results indicate that patients with 
incompletely recovered DGF (GFR < 30 mL/min/1.73 m2) were associated with inferior renal function and 
death-censored graft survival. In contrast, recovered DGF (GFR ≥ 30 mL/min/1.73 m2) had death-censored graft 
survival and renal function similar to those without DGF (controls). DGF was an independent risk factor for 
patient death, regardless of DGF recovery status. The incidence of AR at 12 months has highest in the incomplete 
DGF recovery group.
DGF results from ischaemia-reperfusion injury (IRI) to the graft tissue22. In a non-transplant setting, renal 
IRI lead to AKI with varying reversibility23. There are recent reports that incomplete recovery of renal function 
after AKI is a strong risk factor for decreased long-term survival and poor renal survival7,8. While DGF can be 
considered a severe form of AKI, little is known about recovery after DGF and its influence on long term out-
comes24. In addition, it is difficult to precisely define DGF recovery, consequently, several studies have stratified 
DGF recovery based on the dialysis duration or serum creatinine9–13,25.
Kidney has the ability to repair itself, depending on the severity of the initial damage. Incompletely recovered 
areas may develop into focal fibrosis26,27. In fact, patients with severe AKI have inferior long-term renal outcome 
compared to that in with mild AKI patients6. Similar to the adverse effects of AKI, prolonged DGF, as a reflection 
of severe injury, can worsen renal outcomes9–12. Our results demonstrated that incompletely recovered DGF was 
associated with inferior renal outcomes in terms of death-censored graft survival and renal function. By contrast, 
recovered DGF patients had long-term renal outcomes similar to those of the control group. It is conceivable that 
kidneys with recovered DGF were less severely damaged than kidneys with incompletely recovered DGF.
Reports describing the effects of DGF on patient survival are conflicting. Meta-analysis by Yarlagadda et al. 
revealed no significant association between DGF and mortality4. In contrast, other recent studies revealed that 
DGF is associated with an increased risk for death with functioning graft in both deceased and living donor 
kidney transplant recipients28,29. In addition, DGF is an independent risk factor for cardiovascular disease after 
kidney transplantation30. In the present study, DGF was associated with a greater risk of patient death regardless 
of DGF recovery status, and cardiovascular disease related deaths occurred only in the DGF group.
IRI cause cell damage through several pathways including cell death, microvascular dysfunction, and activa-
tion of immune system31. In particular, IRI leading to DGF increase the expression of human leukocyte antigen 
(HLA) molecules on endothelial cell surfaces, thus increasing the immunogenicity of the allograft24. Some past 
reports show no significant effect of DGF on development of AR32; however, recent studies indicate that DGF is 
an important risk factor for AR, even in the modern era33. In this study, AR occurred more frequently in patients 
with incompletely recovered DGF, which is consistent with previous studies showing an association between 
prolonged DGF and AR10,12.
Prior studies revealed that well-established risk factors for developing DGF, such as donor age, CIT, 
re-transplantation, and HLA mismatches are associated with prolonged DGF10,12. In this study, we found that 
donor final creatinine, old donor, and CIT were associated with incompletely recovered DGF. However, the sever-
ity of IRI is dependent on a complex interplay of pre-transplant injury and subsequent immune responses after 
reperfusion34. Furthermore, clinical factors including medical environment, organ donation rate, and allocation 
system, differ between countries. Hence, it is difficult to generalize and quantify the interaction of clinical factors 
with the DGF recovery status.
Cut-off value for DGF recovery is inherently arbitrary. Although this study could not identify the optimal cut-off 
eGFR value for recovery, our data suggest that DGF recovery status based on GFR at 1 month post-transplantation 
can predict the long-term outcome. Furthermore, this stratification will have an immediate clinical applicabil-
ity, since it is identical to the widely used cut-off for chronic kidney disease stage. Although there is no effective 
treatment for DGF, correct stratification of DGF recovery status in the early postoperative period may contribute 
to improve post-transplant management. Clinical practices including immunosuppressive regimen, threshold for 
biopsy, and cardiovascular work-up might be tailored to individual patients based on their DGF recovery status.
There are several limitations in this study. First, it was performed retrospectively at a single institution. Second, 
we did not measure GFR by inulin clearance but rather used estimated GFR by using MDRD equation. However, 
GFR measurement by inulin clearance is unsuitable for daily clinical practice.
DGF is a clinical entity caused by complex factors with varying severities. Our results suggest that assess-
ment of renal function based on GFR at 1-month after transplantation can provide useful prognostic informa-
tion about long-term outcome. Patients with incompletely recovered DGF present inferior renal function and 
death-censored graft survival at 5-years, compared to patients without DGF and patients with recovered DGF. 
DGF is associated with a greater risk of patient death, regardless of DGF recovery status.
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